MedPage Today

Selinexor OK'd for Myeloma, But Does That Make It a Good Drug?

Following is a transcript of their remarks: Vinay Prasad, MD: I'm back with Aaron Goodman and Dr. Al-Ola Abdallah and we're talking about selinexor. Aaron, selinexor, good drug or great drug? How ...
MedPage Today

Maintenance Selinexor May Boost PFS in TP53 Wild-Type Advanced Endometrial Cancer

SEOUL, South Korea -- Maintenance therapy with selinexor (Xpovio) seemed to substantially extend progression-free survival (PFS) in patients with wild-type TP53 advanced or recurrent endometrial ...
Seeking Alpha

Selinexor's Toxicity Makes It Unlikely For Karyopharm To Ever Be Profitable

Karyopharm Therapeutics develops drugs for cancer and other diseases. Its main drug, Xpovio (selinexor), treats multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL). Despite gaining ...
The American Journal of Managed Care

Selinexor Shows Promise in Combination With Daratumumab, Dexamethasone in RRMM

The oral selective inhibitor of nuclear export could provide a new therapeutic avenue in daratumumab-naive patients with relapsing refractory multiple myeloma (RRMM). The combination of oral selinexor ...
Monthly Prescribing Reference

Oral Selinexor, Pomalidomide, and Dexamethasone Combination Is Safe in Pretreated Patients With Multiple Myeloma

Researchers sought to determine whether selinexor could be safely combined with pomalidomide and dexamethasone in heavily pretreated patients with multiple myeloma. The following article features ...
Nasdaq

Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy

NEWTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced it has submitted a supplemental New Drug ...
ascopubs.org

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma This phase II trial ...
Business Insider

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

SHANGHAI and HONG KONG, May 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and ...
Nasdaq

Antengene Submits NDAs for XPOVIO® (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL

SHANGHAI and HONG KONG, Dec. 3, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and ...
Healio

Selinexor maintenance extends PFS in endometrial cancer subgroup with high unmet need

Please provide your email address to receive an email when new articles are posted on . The oral agent reduced risk for disease progression by 58% vs. placebo among women with TP53 wild-type tumors.
Monthly Prescribing Reference

Selinexor Combo Hits Spleen Target, Misses Symptom Endpoint in Myelofibrosis

While the combination therapy improved spleen outcomes, reductions in absolute total symptom scores were found to be similar between the treatment groups. Topline results were announced from a phase 3 ...